Molecular genetics

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Retrieved on: 
Monday, March 11, 2024
Software, Research, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, QC, GPU, Utrecht University, Pharmacy, IRT, Drug discovery, Radboud University Nijmegen, Cell biology, Biomarker, Molecular genetics, Bruker, University, Ultra, University of Michigan, Proteomics, Peptide, Infection, Pulse, Neoplasm, Glycomics, Lunenfeld-Tanenbaum Research Institute, TIMS, Multimedia, Medical director, BRKR, Pathology, Medical device

At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.

Key Points: 
  • At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.
  • The rapid advances in deep, at-scale proteomics, glycomics and peptidomics research solutions complement other performance-leading life-science tools for the post-genomic era by Bruker.
  • Bruker enhances its timsTOF HT and timsTOF Ultra systems with the new software Novor v2.0 for de novo immunopeptidomic profiling.
  • Our software suite supports the analysis of PASEF data, and we are delighted that Bruker now offers it with timsTOF instruments.

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™

Retrieved on: 
Tuesday, January 23, 2024
RAINBOW, NPC, Glycogen storage disease, GM2, Patient, Research, GM1, Niemann–Pick disease, Gait, Science, Sleep disorder, Molecular genetics, Gangliosidosis, Safety, Central nervous system, Congress, Biomarker, Pharmacokinetics, Metabolism, Pharmaceutical industry

As well as data from PRONTO, Azafaros will present details of its Phase 2 RAINBOW study, aimed at investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of nizubaglustat in patients with GM2 gangliosidosis or NPC.

Key Points: 
  • As well as data from PRONTO, Azafaros will present details of its Phase 2 RAINBOW study, aimed at investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of nizubaglustat in patients with GM2 gangliosidosis or NPC.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO) - patients’ and caregivers’ assessments.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO)- baseline clinical data.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO) - evaluation of different assessments.

Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Drug development, Molecular genetics, Research, FDA, Inflammation, Roche, Doctor of Philosophy, Heidelberg University, Therapy, Gastrointestinal cancer, Plexxikon, University, Max Planck Society, Wellington Partners, Growth, Patient

"We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.

Key Points: 
  • "We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.
  • "Peter is a recognized leader in the biotech industry and his extensive experience in corporate strategy and drug development will be invaluable to Enterome’s future growth and success.
  • I’d also like to thank Roger for his invaluable contributions to Enterome during his time on the Board."
  • Dr. Hirth possesses a wealth of experience and an exceptional track record in the biopharmaceutical industry.

Nature Medicine Study Validates PredicineBEACON™ MRD Liquid Biopsy Assay in Genentech’s Phase 1b Clinical Trial of Divarasib Plus Cetuximab in CRC

Retrieved on: 
Monday, December 11, 2023
Phase, Drug resistance, Urine, Associate, Lung cancer, CRC, Medicine, Molecular genetics, MRD, Plasma, Colorectal cancer, Disease, Blood, NEJM, Liquid biopsy, Cetuximab, Liquid, Genentech, Publication, Patient, NSCLC, Medical imaging

This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech's Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC).

Key Points: 
  • This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech's Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC).
  • This study exemplifies Predicine's continued leadership in the realm of liquid biopsy technology innovation and MRD.
  • Consistent with the outcomes of the prior Phase 1 clinical trial, PredicineBEACON™ showcased remarkable biomarker results in the Phase 1b clinical trial of Divarasib Plus Cetuximab in CRC patients.
  • The enhanced antitumor activity observed in this study reinforces the clinical utility of liquid biopsy profiling in evaluating the Phase 1b clinical trial of combined therapy in CRC patients.

STRANAHAN'S COLORADO WHISKEY APPOINTS NEW HEAD BLENDER, JUSTIN ADEN

Retrieved on: 
Monday, October 9, 2023
Diamond, Diamond Peak, Michigan State University, University, Single malt, Blender, Molecular genetics, Stranahan's Colorado Whiskey, Snowflake, Distillation, Research, Ethanol, Fermentation, Specialization, Unit production manager, Beer, Liquor, MSU, Microbiology

DENVER, Oct. 9, 2023 /PRNewswire/ -- Stranahan's Colorado Whiskey©, the number one-sellingi and most-awardedii American Single Malt, is pleased to announce the appointment of Justin Aden as its first Head Blender. In this critical role, Aden will oversee the intricate process of blending, distillation, and maturation of Stranahan's diverse range of American Single Malt whiskies.

Key Points: 
  • DENVER, Oct. 9, 2023 /PRNewswire/ -- Stranahan's Colorado Whiskey©, the number one-sellingi and most-awardedii American Single Malt, is pleased to announce the appointment of Justin Aden as its first Head Blender.
  • In this critical role, Aden will oversee the intricate process of blending, distillation, and maturation of Stranahan's diverse range of American Single Malt whiskies.
  • "It is an honor to be entrusted to take the reins as the first Head Blender of beloved Stranahan's Colorado Whiskey," says Aden.
  • Along with his tenure at MSU, Aden has served as Head Distiller and Production Manager at Headframe Spirits Distilling, and as Distiller, Blender and Head of Operations at Valentine Distilling Company.

ICHNOS SCIENCES PROMOTES DEAN THOMAS TO GENERAL COUNSEL

Retrieved on: 
Tuesday, October 3, 2023
University, General counsel, Intellectual property, Research, King's College London, Associate, Master of Laws, Dean Thomas, Molecular genetics, Trace fossil classification, United Kingdom, Nursing, Dean

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced the promotion of Dean Thomas to the position of General Counsel, effective immediately.

Key Points: 
  • NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced the promotion of Dean Thomas to the position of General Counsel, effective immediately.
  • "During his tenure at Ichnos, Dean has demonstrated a deep understanding of the intricacies of life sciences—and oncology foremost.
  • We are pleased to welcome him to our executive leadership team as our General Counsel," said Cyril Konto, M.D., President and CEO of Ichnos Sciences.
  • "It is a distinct privilege to continue my career with Ichnos as General Counsel, supporting our company's impressive team as we strive to develop potentially life-changing cancer therapies," said Dean.

Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Retrieved on: 
Monday, October 2, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Biologics license application, Priority review, University, Pediatrics, Molecule, Pharming, Infection, Survival, Skin, MBA, University of California, Disorder, Medication, Șaeș, Molecular genetics, Patient, Cell, Disease, PDUFA, Mortality, Immunology, Principal, UCLA, Pharmacology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Caregiver, Pharmaceutical industry, Microbiology

“Today’s acceptance of the BLA by the FDA marks a significant milestone for Rocket towards our goal of delivering a one-time gene therapy to patients facing the devastating effects of severe LAD-I.

Key Points: 
  • “Today’s acceptance of the BLA by the FDA marks a significant milestone for Rocket towards our goal of delivering a one-time gene therapy to patients facing the devastating effects of severe LAD-I.
  • All primary and secondary endpoints were met, and RP-L201 was very well tolerated in all patients with no treatment related SAEs.
  • “As the Principal Investigator in the U.S., I oversaw treatment of six of the nine LAD-I patients in this trial.
  • All of these children have been in good health with no significant LAD-I-related infections or inflammatory skin lesions since treatment.

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

Retrieved on: 
Thursday, August 24, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, ENT, Human, Nicotinamide adenine dinucleotide, Cell membrane, Diet, Metabolism, Ageing, NMN, NAD, Multimedia, CD73, ChromaDex, Ivan Kropotov, Edward Conze, Assistant, Protein, Molecular genetics, G.H. Raisoni Department of Microbiology and Biotechnology, Canadian International Council, Weill Cornell Medicine, Mouse, Nicotinamide mononucleotide, International Journal of Molecular Sciences, UCLA, Isotope, Environmental Molecular Sciences Laboratory, Pharmaceutical industry, Phosphorus, Immunology, Pharmacology

The results indicate that NMN is primarily converted to nicotinamide and nicotinamide riboside (NR) before being utilized for NAD+ synthesis, with only a small portion of NMN being directly incorporated into NAD+.

Key Points: 
  • The results indicate that NMN is primarily converted to nicotinamide and nicotinamide riboside (NR) before being utilized for NAD+ synthesis, with only a small portion of NMN being directly incorporated into NAD+.
  • These results build on a growing body of research demonstrating that NMN cannot cross the cell membrane directly and must first be converted to NR.
  • Because NR can cross the cell membrane directly, this data, along with other science, indicates that NR is a more efficient NAD+ precursor than NMN.
  • NR and NMN are chemically identical except for a phosphate group present within the structure of NMN.

The FNIH Awards 2023 Lurie Prize in Biomedical Sciences to Navdeep S. Chandel, Ph.D. and Vamsi Mootha, M.D.

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, GSK, Lurie Prize in Biomedical Sciences, DNA, FNIH, Broad Institute, Mitochondrion, Bangladesh Technical Education Board, Cancer, Howard Hughes Medical Institute, Physiology, Biomedical sciences, Mentorship, Systems biology, Inflammation, Genomics, Research, Harvard University, Feinberg School of Medicine, Science, Harvard Medical School, Lurie, Molecular biology, Global Smoke-Free Partnership Award, Protein, Molecular genetics, Common Wealth Award of Distinguished Service, Anne, Johns Hopkins University, Charles, Psychiatry, Wiley Interdisciplinary Reviews: Systems Biology and Medicine, Hospital, Organelle, Ageing, Solomon, Massachusetts General Hospital, Pharmacology, Gene, Vamsi Mootha, Disease, MIT, Dentistry, Nursing, Pharmaceutical industry, Chandel, DRS, Neuroscience, Biochemistry, Medicine

“Each of this year’s Lurie Prize recipients are breaking new ground in mitochondrial research,” said Dr. Julie Gerberding, President and CEO of the FNIH.

Key Points: 
  • “Each of this year’s Lurie Prize recipients are breaking new ground in mitochondrial research,” said Dr. Julie Gerberding, President and CEO of the FNIH.
  • Chandel and Mootha as this year’s Lurie Prize in Biomedical Sciences recipients.
  • The 2023 Lurie Prize will be awarded to both recipients at the FNIH 11th Annual Awards Ceremony on the evening of October 18, 2023, in Washington, D.C.
  • For more information about the Lurie Prize in Biomedical Sciences and a list of previous winners, please visit fnih.org/LuriePrize .

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Retrieved on: 
Thursday, June 29, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Central nervous system, NPC1, CYTH, Brain, Cell, Lung, Trial of the century, Molecular genetics, Spleen, MD, Patient, Manuscript, HIV disease progression rates, Liver, NPC, Niemann–Pick disease, type C, Therapy, DSM-IV codes, Safety, Disease, Pharmaceutical industry

“The data seen to-date provide support for the capacity of Trappsol® Cyclo™ to alter the disease on a biochemical level, including in the central nervous system, and improve clinical signs and symptoms of NPC.

Key Points: 
  • “The data seen to-date provide support for the capacity of Trappsol® Cyclo™ to alter the disease on a biochemical level, including in the central nervous system, and improve clinical signs and symptoms of NPC.
  • In these Phase 2 data, all three doses of Trappsol® Cyclo™ were well-tolerated overall with efficacy across multiple clinical endpoints of intravenous (IV) administration of Trappsol® Cyclo™.
  • Cyclo Therapeutics continues to advance enrollment in its ongoing pivotal Phase 3 study, TransportNPC™ .
  • N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, commented, “We first provided this investigational therapy to address symptoms of NPC back in 2009.